Gluetacs Therapeutics (Shanghai) Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) and eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety through a linker reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders.
The University of Hong Kong has identified reactive oxygen species (ROS)-responsive prodrugs reported to be useful for the treatment of rheumatoid arthritis, cancer and hypertension.
Nido Biosciences Inc. has synthesized bicyclic compounds acting as selective androgen receptor modulators (SARMs) reported to be useful for the treatment of spinal and bulbar muscular atrophy, neurodegeneration and cancer.
UC Davis Comprehensive Cancer Center is partnering with Targagenix Inc. and Northeastern University to study pancreatic ductal adenocarcinoma (PDAC). The partnership will receive nearly US$3 million over 5 years through funding from the National Institutes of Health (NIH).
Sichuan Haisco Pharmaceutical Co. Ltd. has synthesized selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer.
Evaxion Biotech A/S and Pantherna Therapeutics GmbH have announced preclinical proof of concept for the combination of the two companies' key technologies.
Previous research has demonstrated that overexpression or gain-of-function mutations of enhancer of zeste homolog 2 (EZH2) are significantly associated with tumor cell proliferation of a number of cancers.
Acea Therapeutics Inc. and Hangzhou Acea Biosciences Co. Ltd. have described heterocyclic compounds acting as tyrosine kinase inhibitors reported to be useful for the treatment of cancer.
Eternygen UK Ltd. has disclosed 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives acting as sodium-coupled citrate transporter 5 (SLC13A5) inhibitors reported to be useful for the treatment of eating disorders, liver cancer, neurodegeneration, and liver and metabolic diseases.
RSS
